Feb 22 (Reuters) - Drug developer Novavax Inc said on Monday it has completed patient enrollment in the late-stage study of its COVID-19 vaccine in the United States and Mexico. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
Pre-market 04:35:00 pm | |||
4.67 USD | +7.85% | 4.7 | +0.64% |
15/04 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
15/04 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.71% | 651M | |
+0.67% | 42.4B | |
+46.85% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : completes enrollment in U.S. late-stage trial of COVID vaccine